Annual EBITDA
-$14.48 M
+$10.44 M+41.89%
December 31, 2023
Summary
- As of February 12, 2025, RSLS annual EBITDA is -$14.48 million, with the most recent change of +$10.44 million (+41.89%) on December 31, 2023.
- During the last 3 years, RSLS annual EBITDA has risen by +$3.61 million (+19.95%).
- RSLS annual EBITDA is now -31.57% below its all-time high of -$11.01 million, reached on December 31, 2005.
Performance
RSLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$1.76 M
+$292.00 K+14.26%
September 30, 2024
Summary
- As of February 12, 2025, RSLS quarterly EBITDA is -$1.76 million, with the most recent change of +$292.00 thousand (+14.26%) on September 30, 2024.
- Over the past year, RSLS quarterly EBITDA has increased by +$1.30 million (+42.48%).
- RSLS quarterly EBITDA is now at all-time high.
Performance
RSLS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$7.90 M
+$1.30 M+14.11%
September 30, 2024
Summary
- As of February 12, 2025, RSLS TTM EBITDA is -$7.90 million, with the most recent change of +$1.30 million (+14.11%) on September 30, 2024.
- Over the past year, RSLS TTM EBITDA has increased by +$9.42 million (+54.39%).
- RSLS TTM EBITDA is now -22.37% below its all-time high of -$6.45 million, reached on September 30, 2007.
Performance
RSLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RSLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.9% | +42.5% | +54.4% |
| 3 y3 years | +19.9% | +87.8% | +73.0% |
| 5 y5 years | +62.1% | +56.8% | +77.6% |
RSLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +76.1% | at high | +95.7% | at high | +88.9% |
| 5 y | 5-year | at high | +80.1% | at high | +95.7% | at high | +89.2% |
| alltime | all time | -31.6% | +80.1% | at high | +95.7% | -22.4% | +89.2% |
ReShape Lifesciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.76 M(-14.3%) | -$7.90 M(-14.1%) |
| Jun 2024 | - | -$2.05 M(-7.1%) | -$9.19 M(-17.2%) |
| Mar 2024 | - | -$2.20 M(+16.7%) | -$11.11 M(-23.3%) |
| Dec 2023 | -$14.48 M(-41.9%) | -$1.89 M(-38.2%) | -$14.48 M(-16.3%) |
| Sep 2023 | - | -$3.05 M(-22.9%) | -$17.31 M(-6.9%) |
| Jun 2023 | - | -$3.96 M(-29.1%) | -$18.59 M(-19.0%) |
| Mar 2023 | - | -$5.58 M(+18.4%) | -$22.95 M(-7.9%) |
| Dec 2022 | -$24.93 M(-58.9%) | -$4.72 M(+9.0%) | -$24.93 M(-59.3%) |
| Sep 2022 | - | -$4.33 M(-48.0%) | -$61.30 M(-14.2%) |
| Jun 2022 | - | -$8.32 M(+10.0%) | -$71.41 M(+7.6%) |
| Mar 2022 | - | -$7.56 M(-81.6%) | -$66.34 M(+6.0%) |
| Dec 2021 | -$60.62 M(+235.0%) | -$41.09 M(+184.6%) | -$62.61 M(+113.7%) |
| Sep 2021 | - | -$14.44 M(+343.9%) | -$29.30 M(+54.8%) |
| Jun 2021 | - | -$3.25 M(-15.1%) | -$18.93 M(+4.4%) |
| Mar 2021 | - | -$3.83 M(-50.8%) | -$18.12 M(+0.2%) |
| Dec 2020 | -$18.09 M(-75.2%) | -$7.78 M(+91.7%) | -$18.09 M(-48.6%) |
| Sep 2020 | - | -$4.06 M(+65.8%) | -$35.19 M(-40.7%) |
| Jun 2020 | - | -$2.45 M(-35.6%) | -$59.39 M(-18.4%) |
| Mar 2020 | - | -$3.80 M(-84.7%) | -$72.81 M(-0.2%) |
| Dec 2019 | -$72.94 M(+90.6%) | -$24.88 M(-11.9%) | -$72.94 M(+40.1%) |
| Sep 2019 | - | -$28.26 M(+78.1%) | -$52.07 M(+79.6%) |
| Jun 2019 | - | -$15.86 M(+302.6%) | -$29.00 M(-13.6%) |
| Mar 2019 | - | -$3.94 M(-1.7%) | -$33.55 M(-12.3%) |
| Dec 2018 | -$38.26 M(+17.7%) | -$4.01 M(-22.8%) | -$38.26 M(-10.4%) |
| Sep 2018 | - | -$5.19 M(-74.6%) | -$42.72 M(-9.9%) |
| Jun 2018 | - | -$20.42 M(+136.1%) | -$47.43 M(+40.3%) |
| Mar 2018 | - | -$8.65 M(+2.2%) | -$33.82 M(+4.0%) |
| Dec 2017 | -$32.51 M(+70.0%) | -$8.47 M(-14.5%) | -$32.51 M(+17.2%) |
| Sep 2017 | - | -$9.90 M(+45.6%) | -$27.74 M(+20.9%) |
| Jun 2017 | - | -$6.80 M(-7.3%) | -$22.93 M(+13.3%) |
| Mar 2017 | - | -$7.34 M(+98.7%) | -$20.23 M(+5.8%) |
| Dec 2016 | -$19.12 M(-21.6%) | -$3.69 M(-27.6%) | -$19.12 M(-13.3%) |
| Sep 2016 | - | -$5.10 M(+24.3%) | -$22.05 M(+7.6%) |
| Jun 2016 | - | -$4.10 M(-34.0%) | -$20.49 M(-13.5%) |
| Mar 2016 | - | -$6.22 M(-6.2%) | -$23.68 M(-2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | -$24.37 M(-4.1%) | -$6.63 M(+87.4%) | -$24.37 M(+2.5%) |
| Sep 2015 | - | -$3.54 M(-51.5%) | -$23.78 M(-7.8%) |
| Jun 2015 | - | -$7.29 M(+5.6%) | -$25.79 M(-0.1%) |
| Mar 2015 | - | -$6.91 M(+14.4%) | -$25.80 M(+1.6%) |
| Dec 2014 | -$25.41 M(+3.0%) | -$6.04 M(+8.9%) | -$25.41 M(-1.1%) |
| Sep 2014 | - | -$5.55 M(-24.1%) | -$25.69 M(-1.9%) |
| Jun 2014 | - | -$7.31 M(+12.2%) | -$26.18 M(+5.1%) |
| Mar 2014 | - | -$6.52 M(+3.0%) | -$24.91 M(+1.0%) |
| Dec 2013 | -$24.67 M(+10.5%) | -$6.32 M(+4.8%) | -$24.67 M(-1.5%) |
| Sep 2013 | - | -$6.04 M(+0.0%) | -$25.06 M(+2.1%) |
| Jun 2013 | - | -$6.04 M(-3.9%) | -$24.56 M(+5.9%) |
| Mar 2013 | - | -$6.28 M(-6.5%) | -$23.19 M(+3.8%) |
| Dec 2012 | -$22.33 M(-10.6%) | -$6.71 M(+21.4%) | -$22.33 M(-4.7%) |
| Sep 2012 | - | -$5.53 M(+18.5%) | -$23.44 M(-6.1%) |
| Jun 2012 | - | -$4.67 M(-13.9%) | -$24.96 M(-2.5%) |
| Mar 2012 | - | -$5.42 M(-30.7%) | -$25.61 M(+2.5%) |
| Dec 2011 | -$24.97 M(+58.9%) | -$7.82 M(+10.9%) | -$24.97 M(+21.3%) |
| Sep 2011 | - | -$7.05 M(+32.9%) | -$20.59 M(+17.4%) |
| Jun 2011 | - | -$5.31 M(+10.9%) | -$17.54 M(+7.9%) |
| Mar 2011 | - | -$4.79 M(+39.0%) | -$16.25 M(+3.4%) |
| Dec 2010 | -$15.71 M(-33.9%) | -$3.44 M(-13.9%) | -$15.71 M(-8.5%) |
| Sep 2010 | - | -$4.00 M(-0.5%) | -$17.18 M(-15.5%) |
| Jun 2010 | - | -$4.02 M(-5.5%) | -$20.34 M(-9.4%) |
| Mar 2010 | - | -$4.25 M(-13.4%) | -$22.44 M(-5.6%) |
| Dec 2009 | -$23.79 M(-33.5%) | -$4.91 M(-31.4%) | -$23.79 M(-5.7%) |
| Sep 2009 | - | -$7.15 M(+16.7%) | -$25.23 M(-10.3%) |
| Jun 2009 | - | -$6.13 M(+9.5%) | -$28.14 M(-14.7%) |
| Mar 2009 | - | -$5.59 M(-12.0%) | -$33.01 M(-7.6%) |
| Dec 2008 | -$35.76 M(+32.3%) | -$6.36 M(-36.8%) | -$35.73 M(-5.6%) |
| Sep 2008 | - | -$10.06 M(-8.5%) | -$37.84 M(+10.5%) |
| Jun 2008 | - | -$11.00 M(+32.3%) | -$34.23 M(+47.3%) |
| Mar 2008 | - | -$8.31 M(-1.9%) | -$23.24 M(+55.7%) |
| Dec 2007 | -$27.03 M(+50.0%) | -$8.47 M(+31.3%) | -$14.92 M(+131.3%) |
| Sep 2007 | - | -$6.45 M | -$6.45 M |
| Dec 2006 | -$18.03 M(+63.7%) | - | - |
| Dec 2005 | -$11.01 M | - | - |
FAQ
- What is ReShape Lifesciences annual EBITDA?
- What is the all time high annual EBITDA for ReShape Lifesciences?
- What is ReShape Lifesciences annual EBITDA year-on-year change?
- What is ReShape Lifesciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly EBITDA year-on-year change?
- What is ReShape Lifesciences TTM EBITDA?
- What is the all time high TTM EBITDA for ReShape Lifesciences?
- What is ReShape Lifesciences TTM EBITDA year-on-year change?
What is ReShape Lifesciences annual EBITDA?
The current annual EBITDA of RSLS is -$14.48 M
What is the all time high annual EBITDA for ReShape Lifesciences?
ReShape Lifesciences all-time high annual EBITDA is -$11.01 M
What is ReShape Lifesciences annual EBITDA year-on-year change?
Over the past year, RSLS annual EBITDA has changed by +$10.44 M (+41.89%)
What is ReShape Lifesciences quarterly EBITDA?
The current quarterly EBITDA of RSLS is -$1.76 M
What is the all time high quarterly EBITDA for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly EBITDA is -$1.76 M
What is ReShape Lifesciences quarterly EBITDA year-on-year change?
Over the past year, RSLS quarterly EBITDA has changed by +$1.30 M (+42.48%)
What is ReShape Lifesciences TTM EBITDA?
The current TTM EBITDA of RSLS is -$7.90 M
What is the all time high TTM EBITDA for ReShape Lifesciences?
ReShape Lifesciences all-time high TTM EBITDA is -$6.45 M
What is ReShape Lifesciences TTM EBITDA year-on-year change?
Over the past year, RSLS TTM EBITDA has changed by +$9.42 M (+54.39%)